Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.

ABSTRACT: Lung cancer is Asia's most prevalent cancer, accounting for the highest global patient share. A significant number of non-small cell lung cancer (NSCLC) patients in Asia exhibit mutations in the epidermal growth factor receptor (EGFR). Although clinical outcomes are improving with newer therapies, challenges persist in the effective management of EGFR mutant (EGFRm) NSCLC. Given the substantial disease burden, understanding the current diagnostic and treatment patterns for EGFRm NSCLC from an Asian perspective is essential. This expert opinion presents recommendations from Asian experts on molecular testing and treatment of first-line and second-line EGFRm NSCLC. The recommendations aim to optimize patient outcomes by providing a comprehensive approach to diagnosis and management, consider

SUBMITTER: Chang GC 

PROVIDER: S-EPMC12375841 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature